scispace - formally typeset
Search or ask a question
JournalISSN: 2287-4208

The World Journal of Men's Health 

Korean Society for Sexual Medicine and Andrology
About: The World Journal of Men's Health is an academic journal published by Korean Society for Sexual Medicine and Andrology. The journal publishes majorly in the area(s): Medicine & Internal medicine. It has an ISSN identifier of 2287-4208. It is also open access. Over the lifetime, 1105 publications have been published receiving 9801 citations. The journal is also known as: WJMH.


Papers
More filters
Journal ArticleDOI
TL;DR: This review highlights the mechanisms of ROS production, the physiological and pathophysiological roles of ROS in relation to the male reproductive system, and recent advances in diagnostic methods; it also explores the benefits of using antioxidants in a clinical setting.
Abstract: Infertility affects approximately 15% of couples trying to conceive, and a male factor contributes to roughly half of these cases. Oxidative stress (OS) has been identified as one of the many mediators of male infertility by causing sperm dysfunction. OS is a state related to increased cellular damage triggered by oxygen and oxygen-derived free radicals known as reactive oxygen species (ROS). During this process, augmented production of ROS overwhelms the body's antioxidant defenses. While small amounts of ROS are required for normal sperm functioning, disproportionate levels can negatively impact the quality of spermatozoa and impair their overall fertilizing capacity. OS has been identified as an area of great attention because ROS and their metabolites can attack DNA, lipids, and proteins; alter enzymatic systems; produce irreparable alterations; cause cell death; and ultimately, lead to a decline in the semen parameters associated with male infertility. This review highlights the mechanisms of ROS production, the physiological and pathophysiological roles of ROS in relation to the male reproductive system, and recent advances in diagnostic methods; it also explores the benefits of using antioxidants in a clinical setting.

868 citations

Journal ArticleDOI
TL;DR: Several animal and human studies have shown sex differences in gut microbiota, and this work reviews these studies to discuss the sex-dependent differences as well as the possible mechanisms involved.
Abstract: Humans carry numerous symbiotic microorganisms in their body, most of which are present in the gut. Although recent technological advances have produced extensive research data on gut microbiota, there are various confounding factors (e.g., diet, race, medications) to consider. Sex is one of the important variables affecting the gut microbiota, but the association has not yet been sufficiently investigated. Although the results are inconsistent, several animal and human studies have shown sex differences in gut microbiota. Herein, we review these studies to discuss the sex-dependent differences as well as the possible mechanisms involved.

287 citations

Journal ArticleDOI
TL;DR: This review focuses on the functions of AR in prostate cancer and the development of CRPC and promising new agents against CRPC.
Abstract: Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding domain, hinge region, and ligand-binding domain. AR plays pivotal roles in prostate cancer, especially castration-resistant prostate cancer (CRPC). Androgen deprivation therapy can suppress hormone-naive prostate cancer, but prostate cancer changes AR and adapts to survive under castration levels of androgen. These mechanisms include AR point mutations, AR overexpression, changes of androgen biosynthesis, constitutively active AR splice variants without ligand binding, and changes of androgen cofactors. Studies of AR in CRPC revealed that AR was still active in CRPC, and it remains as a potential target to treat CRPC. Enzalutamide is a second-generation antiandrogen effective in patients with CRPC before and after taxane-based chemotherapy. However, CRPC is still incurable and can develop drug resistance. Understanding the mechanisms of this resistance can enable new-generation therapies for CRPC. Several promising new AR-targeted therapies have been developed. Apalutamide is a new Food and Drug Administration-approved androgen agonist binding to the ligand-binding domain, and clinical trials of other new AR-targeted agents binding to the ligand-binding domain or N-terminal domain are underway. This review focuses on the functions of AR in prostate cancer and the development of CRPC and promising new agents against CRPC.

240 citations

Journal ArticleDOI
Ashok Agarwal1, Neel Parekh1, Manesh Kumar Panner Selvam1, Ralf Henkel1, Ralf Henkel2, Rupin Shah3, Sheryl T. Homa4, Ranjith Ramasamy5, Edmund Y. Ko6, Kelton Tremellen7, Sandro C. Esteves8, Sandro C. Esteves9, Ahmad Majzoub10, Ahmad Majzoub1, Juan G. Alvarez11, David K. Gardner12, Channa N. Jayasena13, Channa N. Jayasena14, Jonathan Ramsay13, Chak-Lam Cho15, Ramadan A Saleh16, Denny Sakkas, James M. Hotaling17, Scott Lundy1, Sarah C. Vij1, Joel L. Marmar18, Jaime Gosálvez19, Edmund Sabanegh1, Hyun Jun Park20, Armand Zini21, Parviz Kavoussi, Sava Micic, Ryan P. Smith22, Gian Maria Busetto23, Mustafa Emre Bakircioglu, Gerhard Haidl24, Giancarlo Balercia, Nicolás Garrido Puchalt, Moncef Ben-Khalifa, Nicholas N. Tadros25, Jackson Kirkman-Browne26, Sergey I. Moskovtsev27, Xuefeng Huang28, Edson Borges, Daniel R. Franken29, Natan Bar-Chama30, Yoshiharu Morimoto, Kazuhisa Tomita, Vasan Satya Srini, Willem Ombelet31, Elisabetta Baldi32, Monica Muratori32, Yasushi Yumura33, Sandro La Vignera34, Raghavender Kosgi, Marlon Martinez35, Donald P. Evenson, Daniel Suslik Zylbersztejn, Matheus Roque, Marcello Cocuzza36, Marcelo Vieira37, Assaf Ben-Meir38, Raoul Orvieto39, Raoul Orvieto40, Eliahu Levitas41, Amir Wiser39, Amir Wiser42, Mohamed Arafa10, Vineet Malhotra, Sijo Parekattil43, Haitham Elbardisi10, Luiz Carvalho, Rima Dada44, Christophe Sifer, Pankaj Talwar45, Ahmet Gudeloglu46, Ahmed M A Mahmoud, Khaled Terras, Chadi Yazbeck, Bojanic Nebojsa47, Damayanthi Durairajanayagam48, Ajina Mounir49, Linda G. Kahn50, Saradha Baskaran1, Rishma Pai3, Donatella Paoli23, Kristian Leisegang2, Mohamed Reza Moein, Sonia Malik, Önder Yaman, Luna Samanta51, Fouad Bayane, Sunil Jindal, Muammer Kendirci, Barış Altay52, Dragoljub Perovic, Avi Harlev41 
TL;DR: Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants) and may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose.
Abstract: Despite advances in the field of male reproductive health, idiopathic male infertility, in which a man has altered semen characteristics without an identifiable cause and there is no female factor infertility, remains a challenging condition to diagnose and manage. Increasing evidence suggests that oxidative stress (OS) plays an independent role in the etiology of male infertility, with 30% to 80% of infertile men having elevated seminal reactive oxygen species levels. OS can negatively affect fertility via a number of pathways, including interference with capacitation and possible damage to sperm membrane and DNA, which may impair the sperm's potential to fertilize an egg and develop into a healthy embryo. Adequate evaluation of male reproductive potential should therefore include an assessment of sperm OS. We propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, including many patients who were previously classified as having idiopathic male infertility. Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants). Current treatment protocols for OS, including the use of antioxidants, are not evidence-based and have the potential for complications and increased healthcare-related expenditures. Utilizing an easy, reproducible, and cost-effective test to measure ORP may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose. With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, future research endeavors can facilitate the development of evidence-based treatments that target its underlying cause.

229 citations

Performance
Metrics
No. of papers from the Journal in previous years
YearPapers
202364
202290
2021108
202047
201951
201831